



RESTORING **BOWEL AND BLADDER CONTROL** FOR PEOPLE WITH NEUROLOGICAL DISORDERS, DIABETES, AND THE ELDERLY

Anthony DiTonno, CEO



INVESTMENT HIGHLIGHTS



Capital efficient plan to NDA filing for lead program

- Clinically validated 505(b)(2) pathway
- Multiple early clinical milestones



NIH funded program w/o dilutive funding for second program



Robust IP coverage



Big underserved, unrecognized markets

2 M

individuals with disabilities in the US

5 M

seniors with mobility challenges in the US

MANAGEMENT TEAM



Anthony DiTonno
CEO



Ed Burgard, PhD
President



Karl Thor, PhD
CSO



Lesley Marson, PhD
VP Preclinical R&D



Daniel Ricca, PhD
VP Chemistry



Mary Katofiasc
Sr Dir Operations



Advocacy
support



CURRENT STANDARD OF CARE




Imagine if every time you had to urinate or defecate you needed to catheterize your bladder and manually remove stool with your or your caregiver's hands....


You've just imagined why restoring bowel and bladder control are so important for people with spinal cord injury or disease.

- C2 quadriplegic


Bladder voiding




Catheters



Bowel voiding




Enemas



Manual extraction

DIGNIFY'S APPROACH: Drug - Induced On - Demand Voiding





DRUG PROGRAMS

DTI-301

On-demand defecation



Suppository



DTI-117


On-demand urination and defecation



Sublingual



Intramuscular




DTI-301: ON-DEMAND DEFECATION

505(b)(2) pathway



DTI-301
(suppository)



DTI-301: Proven Development Pathway

- Endo Pharmaceuticals

- Lidoderm

- **75 pts/\$1.4B** Revenue at peak 2023
- Approved 1999
- Indication: Painful PHN

- Corcept Therapeutics


- Korlym

- **50 pts/~\$450M** Revenue at peak 2023
- Approved 2012
- Indication: Cushing's syndrome




DTI-301: ON-DEMAND DEFECATION

Dose-dependent defecation in rats within 5 minutes




Minimal systemic exposure following intrarectal dosing



DTI-117: ON-DEMAND URINATION, DEFECATION

This program is fully funded through Phase 1 clinical by the NIH



GROWTH AND EXPANSION

\$800 K

Founders/Loan/Grant



one north carolina
Small Business Program



\$3 M

Seed



ESHELMAN
VENTURES



RACAPITAL

> \$20 M

Non-Dilutive



one north carolina
Small Business Program



PROGRAMS VALIDATED BY VCS, NIH, DEFENSE DEPT

> Competitive funding

> Scientific rigor

> Unmet medical need

\$20 M

SEEKING SERIES

A EQUITY

FINANCING



NDA in 3 years



**Multiple early
clinical milestones**



**Two programs for
the price of one**

Restoring **bowel and bladder control** for people with neurological disorders, diabetes, and the elderly

ditonno@dignifytherapeutics.com